Tag: Parkinson's disease
Olatec Therapeutics set to launch dapansutrile Phase 2 trial in Parkinson’s disease
Olatec Therapeutics, Inc. (Olatec), a leader in the field of selective NLRP3 inhibitors, has embarked on a journey to tackle Parkinson's disease, a neurodegenerative disorder ... Read More
Inhibikase Therapeutics advances Parkinson’s disease treatment with risvodetinib clinical trials
Inhibikase Therapeutics, Inc. (Nasdaq: IKT), a clinical-stage pharmaceutical company, has announced the publication of its Phase 1 clinical studies for risvodetinib (risvo), a potential disease-modifying ... Read More
Zydus Lifesciences to launch Phase 2 Parkinson’s disease trial of ZYIL1
Zydus Lifesciences Limited, a globally recognized pharmaceutical company, has recently obtained the USFDA's approval to commence Phase II clinical study of its NLRP3 inhibitor, ZYIL1, ... Read More
AbbVie to acquire Cerevel Therapeutics for $8.7bn to expand neuroscience research
AbbVie Inc. (NYSE: ABBV) and Cerevel Therapeutics (NASDAQ: CERE) have announced a definitive agreement in which AbbVie will acquire Cerevel Therapeutics. The transaction, valued at ... Read More
SPARC achieves enrollment goal in PROSEEK Phase 2 Parkinson’s trial
Sun Pharma Advanced Research Company Ltd. (SPARC) has announced the successful completion of patient enrollment for the PROSEEK study, a significant global Phase 2 clinical ... Read More
ABL Bio, Sanofi sign $1bn deal for Parkinson’s candidate ABL301
ABL Bio has bagged a global collaboration and licensing deal worth up to $1.06 billion with Sanofi to develop and commercialize its drug candidate ABL301 ... Read More
Lilly wraps up acquisition of gene therapy company Prevail Therapeutics
Eli Lilly and Company (Lilly) has completed its previously announced deal worth up to $1.04 billion of US gene therapy company Prevail Therapeutics. The US ... Read More
Lilly to acquire US gene therapy company Prevail Therapeutics in $1bn deal
Eli Lilly and Company (Lilly) has signed a deal worth up to $1.04 billion to acquire Prevail Therapeutics, a US gene therapy company engaged in ... Read More
Cerevel launches phase 3 Parkinson’s disease clinical trials for tavapadon
Parkinson’s disease clinical trials : Cerevel Therapeutics, a US biopharma company, has initiated a phase 3 clinical trial program for evaluating tavapadon in Parkinson’s disease ... Read More
resTORbio to stop RTB101 development for symptomatic respiratory illness
resTORbio has discontinued the development of RTB101, a TORC1 inhibitor, for the prevention of clinically symptomatic respiratory illness (CSRI) after the drug failed to meet ... Read More